Provided by Tiger Trade Technology Pte. Ltd.

Eloxx Pharmaceuticals (Uplisting)

10.69
+0.04000.38%
Post-market: 10.690.00000.00%19:30 EST
Volume:14.98K
Turnover:157.94K
Market Cap:43.69M
PE:-4.35
High:10.94
Open:10.90
Low:9.90
Close:10.65
52wk High:23.40
52wk Low:0.0000
Shares:4.09M
Float Shares:998.00K
Volume Ratio:0.62
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4550
EPS(LYR):-5.3408
ROE:-615.23%
ROA:-97.59%
PB:1.06
PE(LYR):-2.00

Loading ...

Eloxx Pharmaceuticals’ exaluren shows efficacy in Alport syndrome trial

TIPRANKS
·
Nov 19

Eloxx's Exaluren Increases Kidney Collagen IV in Phase 2a Alport Syndrome Study

Reuters
·
Nov 19

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

THOMSON REUTERS
·
Nov 19

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Henry Schein (HSIC) and Eloxx Pharmaceuticals (ELOX)

TIPRANKS
·
Nov 17

Eloxx Pharmaceuticals Inc Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 16

Eloxx Pharmaceuticals Q3 Net Loss Widens on Higher Costs

Reuters
·
Nov 16

Eloxx Pharmaceuticals Names T.R. Srinivas Chief Medical Officer

Reuters
·
Nov 16

Eloxx Pharma Q3 EPS $(0.49) Beats $(0.58) Estimate

Benzinga Earnings
·
Nov 16

Eloxx Pharmaceuticals to Present at 3rd Annual Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 03

FDA Clears Eloxx's Exaluren for Phase 2 Trial in ADPKD

Reuters
·
Oct 29

Eloxx Pharmaceuticals - Express to Randomize 60 Patients; First Dosing in 3Q 2027; Topline Data in 1H 2029

THOMSON REUTERS
·
Oct 29

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation Adpkd

THOMSON REUTERS
·
Oct 29

US Research Roundup-Coca-Cola, Ecolab, Visa

Reuters
·
Oct 28

Eloxx Pharmaceuticals Inc : Guggenheim Cuts Target Price to $40 from $43

THOMSON REUTERS
·
Oct 28

Eloxx Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Geno J. Germano

Reuters
·
Oct 22

Eloxx Pharmaceuticals Names T.R. Srinivas Chief Medical Officer

Reuters
·
Oct 20

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 Express Study Design in Nonsense-Mutation Adpkd and Appoints T.r. Srinivas, M.d., Chief Medical Officer

THOMSON REUTERS
·
Oct 20

Eloxx Pharmaceuticals - First Patient Dosing Expected in 3Q 2027, Topline Data Expected in 1H 2029

THOMSON REUTERS
·
Oct 20

Eloxx Pharmaceuticals Appoints Geno Germano to Board

Reuters
·
Oct 20

Press Release: Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to Its Board of Directors

Dow Jones
·
Oct 20